Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Chemical Medience Markets POCT Device To The U.S. And Canada

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based medical device maker Mitsubishi Chemical Medience began marketing compact automated immunoassay analyzer Pathfast to the U.S. and Canada. FDA approved the device along with N-Terminal proBNP (brain natriuretic peptide) testing as a marker of congestive heart failure. A point-of-care testing device, PATHFAST is used for night and emergency care testing and has been marketed in Europe and Korea. The company has signed distribution agreements with North American distributors and hopes to get six more test reagents approved by the FDA by this December. Mitsubishi Chemical estimates within three years that Pathfast will reach 10 percent of the BNP testing market with ¥4 billion in sales. (Click here for more - Japanese language

You may also be interested in...



What Came Before COVID-19: Two Centuries Of Vaccine Development

Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’

COVID-19 Vaccines Blaze New Path In the History Of Vaccine Development

Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.

CV Sciences Reboots PlusCBD Brand While Counting On New Immunity Products During Flu Season

CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel